about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Sci­en­tists hold out hope for re­gen­er­a­tive in­fu­sion via brain im­plant — de­spite fail­ing its first test in ...

7 years ago
R&D

Parex­el re­cruits top FDA on­col­o­gy ex­pert Amy Mc­K­ee for new R&D ini­tia­tive

7 years ago
People
Pharma

Am­i­cus blue­prints growth plans for Philly-based gene ther­a­py group; Cash-strapped Com­pu­gen re­struc­tures, cuts 35 ...

7 years ago
News Briefing

Cor­nell re­searchers to launch ear­ly tri­al of gene ther­a­py aimed — ul­ti­mate­ly — at pre­vent­ing Alzheimer's

7 years ago
Discovery
Cell/Gene Tx

CRISPR Ther­a­peu­tics treats first pa­tient with gene edit­ing tech; Am­i­cus nabs 'break­through' sta­tus for Pompe drug

7 years ago
News Briefing

Un­fazed by re­cent car­dio set­backs, No­var­tis takes an­oth­er PhI­II chal­lenge head-on with Akcea drug

7 years ago
Pharma

Pfiz­er spin­out woos Ot­su­ka vet Ray­mond Sanchez to lead CNS pipeline work; Joe An­der­son re­turns to Ar­ix helm

7 years ago
Peer Review

Star­board plots board coup af­ter buy­ing in­to Bris­tol-My­ers in lead-up to Cel­gene buy­out vote

7 years ago
Deals

Off-the-shelf CAR-T from stem cells? An ear­ly look at UCLA tech — li­censed by Gilead

7 years ago
Discovery

Ap­ply­ing CRISPR to Duchenne, Duke re­searchers spot­light 1-year mouse da­ta in Sarep­ta-spon­sored study

7 years ago
Discovery

Backed by Or­biMed and J&J to build pre­ci­sion bac­te­ria-killing tool, Bio­mX adds a slate of in­vestors in $32M Se­ries B

7 years ago
Financing
Startups

Is­rael's Im­mune Phar­ma waves the white flag af­ter fail­ing to se­cure deals for in­flam­ma­tion drug

7 years ago
R&D

Throw­ing in the tow­el, trou­bled an­tibi­ot­ic mak­er Ar­a­digm files for Chap­ter 11

7 years ago
R&D

J&J R&D vet Pe­ter Tum­mi­no joins the Big Phar­ma ex­o­dus, leap­ing to Nim­bus as CSO; Ca­dent taps Jodie Mor­ri­son for CEO

7 years ago
Peer Review

James Wil­son turns to old men­tor for gene ther­a­py star­tup's star-stud­ded $115M launch round

7 years ago
Financing
Startups

Mo­tif Bio's turn­around quest for once-re­ject­ed an­tibi­ot­ic hits the CRL wall

7 years ago
R&D

In HKEX's first test in 2019, CStone seeks up to $304M in IPO for­tune

7 years ago
Financing
China

Charles Riv­er drops $510M to bag non-clin­i­cal CRO; Mag­pie rais­es $14.8M Se­ries B to mod­ern­ize tra­di­tion­al Chi­nese ...

7 years ago
News Briefing

Affini­vax, Astel­las be­gin clin­i­cal quest to beat Pfiz­er's Go­liath with a new kind of pneu­mo­coc­cal vac­cine

7 years ago
R&D

Chi­na vows to con­tin­ue speed­ing up drug ap­provals, ex­pand tax cuts; Sor­ren­to/Yuhan JV re­ceives $40M fi­nanc­ing

7 years ago
News Briefing

Hill­house Cap­i­tal en­dors­es Chi­na-based Hai­He Bio­phar­ma's can­cer pipeline in $146M round

7 years ago
Financing
China

FDA promis­es speedy re­view on mov­ing Mer­ck­'s Keytru­da up as first-line head and neck can­cer ther­a­py

7 years ago
Pharma

So­lid­i­fy­ing a new cor­po­rate struc­ture, IFM launch­es sec­ond unit fo­cused on cGAS-STING

7 years ago
Startups

Mor­phoSys taps Baven­cio lead for US op­er­a­tions; Two top FDA of­fi­cials move to in­dus­try

7 years ago
Peer Review
First page Previous page 103104105106107108109 Next page Last page
A service from the Financial Times